Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis
Abstract Amyotrophic lateral sclerosis (ALS) is a paralytic, heterogeneous and progressive disease characterized by the degeneration of both upper and lower motor neurons. Several studies about the effects of statins drug on the risk of ALS showed contradictory results and evidence for this is inconclusive. So we aimed to perform a meta-analysis on previous studies to clarify the association between statin use and risk of ALS. The databases including PubMed, Scopus, and Web of science were searched in February 2021 for studies that reported the association between statin use and risk of ALS. The eligible studies had to provide a report on the effect of statin and the incidence of ALS while comparing it to the control group. Articles that had low statin exposure time, the absence of a control group and an unknown number of ALS patients were excluded. The rate ratio and 95% confidence interval (CI) were used for association measures in case–control and cohort studies. After full-text and abstract review, data from 8 studies with a total of 547,622 participants and 13,890 cases of ALS were entered in the present meta-analysis. We combined eight studies using a random-effect model and the RR for statin users among groups was 0.98 (95% CI 0.80–1.20) which indicates no association between statin and incidence of ALS. Also high heterogeneity was detected across the studies (Q value = 26.62, P = .00; I2 = 72.71%). In our meta-analysis study, we found no association between statin use and an increase in ALS incidence. This result is in line with some previous studies and provides strong evidence that denies the possible association between statin uptake and disease induction..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
|---|---|
| Enthalten in: |
Acta neurologica Belgica - 122(2021), 4 vom: 28. Juli, Seite 979-986 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nabizadeh, Fardin [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Belgian Neurological Society 2021 |
|---|
| doi: |
10.1007/s13760-021-01753-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079197193 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079197193 | ||
| 003 | DE-627 | ||
| 005 | 20230513235318.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13760-021-01753-8 |2 doi | |
| 035 | |a (DE-627)OLC2079197193 | ||
| 035 | |a (DE-He213)s13760-021-01753-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Nabizadeh, Fardin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Belgian Neurological Society 2021 | ||
| 520 | |a Abstract Amyotrophic lateral sclerosis (ALS) is a paralytic, heterogeneous and progressive disease characterized by the degeneration of both upper and lower motor neurons. Several studies about the effects of statins drug on the risk of ALS showed contradictory results and evidence for this is inconclusive. So we aimed to perform a meta-analysis on previous studies to clarify the association between statin use and risk of ALS. The databases including PubMed, Scopus, and Web of science were searched in February 2021 for studies that reported the association between statin use and risk of ALS. The eligible studies had to provide a report on the effect of statin and the incidence of ALS while comparing it to the control group. Articles that had low statin exposure time, the absence of a control group and an unknown number of ALS patients were excluded. The rate ratio and 95% confidence interval (CI) were used for association measures in case–control and cohort studies. After full-text and abstract review, data from 8 studies with a total of 547,622 participants and 13,890 cases of ALS were entered in the present meta-analysis. We combined eight studies using a random-effect model and the RR for statin users among groups was 0.98 (95% CI 0.80–1.20) which indicates no association between statin and incidence of ALS. Also high heterogeneity was detected across the studies (Q value = 26.62, P = .00; I2 = 72.71%). In our meta-analysis study, we found no association between statin use and an increase in ALS incidence. This result is in line with some previous studies and provides strong evidence that denies the possible association between statin uptake and disease induction. | ||
| 650 | 4 | |a Statins | |
| 650 | 4 | |a Amyotrophic lateral sclerosis | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Balabandian, Mohammad |4 aut | |
| 700 | 1 | |a Sharafi, Amir Mohammad |4 aut | |
| 700 | 1 | |a Ghaderi, Ali |4 aut | |
| 700 | 1 | |a Rostami, Mohammad Reza |4 aut | |
| 700 | 1 | |a Naser Moghadasi, Abdorreza |0 (orcid)0000-0002-8598-0911 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta neurologica Belgica |d Springer International Publishing, 1970 |g 122(2021), 4 vom: 28. Juli, Seite 979-986 |w (DE-627)166203645 |w (DE-600)127315-2 |w (DE-576)014524147 |x 0300-9009 |7 nnns |
| 773 | 1 | 8 | |g volume:122 |g year:2021 |g number:4 |g day:28 |g month:07 |g pages:979-986 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s13760-021-01753-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 122 |j 2021 |e 4 |b 28 |c 07 |h 979-986 | ||